Effects of Growth Hormone Treatment on Lipid Profiles
- 87 Downloads
To assess the effects of growth hormone (GH) on lipid profiles in children and whether the effect is pharmacological.
The authors determined serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and low-density lipoprotein cholesterol (LDL-C) every year during 3-y GH treatment in 48 GH deficient (GHD) short children and 22 children with short stature born small for gestational age (SGA).
The abnormally high levels of TC, non-HDL-C, and LDL-C showed a high frequency in GHD short children compared with epidemiological studies in Japan. The high prevalence of high level of TC was also shown in SGA short children. Three-year GH treatment decreased serum TC, non-HDL-C, and LDL-C levels in both patient groups.
GH treatment is clearly a pharmacological therapy in SGA short children and so may also be in GHD short children at the Japanese standard therapeutic dose. Taken together, GH improves lipid profiles, and its effect has the possibility of medical properties.
KeywordsGrowth hormone Lipid Cholesterol Growth hormone deficiency Small for gestational age
TK designed this study; KT analyzed the data, and the other authors acquired the data; TK drafted the manuscript, and the other authors revised it. All authors have read and approved the final manuscript. TK will act as guarantor for the paper.
Compliance with Ethical Standards
Ethics Committee Approval
This study was approved by the ethics committee of the National Hospital Organization, Okayama Medical Center. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments.
Conflict of Interest
Source of Funding
Supported by National Hospital Organization, Okayama Medical Center.
- 6.Chihara K, Koledova E, Shimatus A, et al. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. Eur J Endocrinol. 2005;153:57–65.Google Scholar
- 12.Foster C, Burton A, Scholl J, Scott ML, Gunter V, McCormick K. Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocri Met. 2014;27:909–14.Google Scholar
- 13.Kuromaru R, Kohno H, Ueyama N, Hassan HMS, Honda S, Hara T. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabokic effects. J Clin Endocrinol Metab. 1998;83:3890–6.PubMedGoogle Scholar
- 16.Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000;85:3786–92.PubMedGoogle Scholar
- 17.van Dijk M, Bannink EMN, van Pareren YK, Muldre PGH, Hokken-Koelega ACS. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab. 2007;92:160–5.CrossRefPubMedGoogle Scholar
- 21.Approved Guideline - Evaluation of precision performance of clinical chemistry devices, EP5-A. 1999. National Committee for Clinical Laboratory StandardsGoogle Scholar
- 24.Kubo T, Takahashi K, Furujo M, et al. Usefulness of non-fasting lipid parameters in children. J Pediatr Endocrinol Met. 2017;30:77–83.Google Scholar
- 31.Finkelstein JW, Roffwarg HP, Boyard RM, Kream J, Hellman L. Age-related changes in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab. 1972;35:665–70.Google Scholar